668 related articles for article (PubMed ID: 33805598)
1. Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.
Kreps LM; Addison CL
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805598
[TBL] [Abstract][Full Text] [Related]
2. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
3. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
4. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
5. Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis.
Hu W; Zhang L; Dong Y; Tian Z; Chen Y; Dong S
Cell Mol Life Sci; 2020 Dec; 77(24):5149-5169. PubMed ID: 32556373
[TBL] [Abstract][Full Text] [Related]
6. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
7. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
Cascini C; Chiodoni C
Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic targets for cancer bone metastasis.
Krzeszinski JY; Wan Y
Trends Pharmacol Sci; 2015 Jun; 36(6):360-73. PubMed ID: 25962679
[TBL] [Abstract][Full Text] [Related]
9. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
11. Overcoming immunosuppression in bone metastases.
Reinstein ZZ; Pamarthy S; Sagar V; Costa R; Abdulkadir SA; Giles FJ; Carneiro BA
Crit Rev Oncol Hematol; 2017 Sep; 117():114-127. PubMed ID: 28600175
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.
Safari E; Ghorghanlu S; Ahmadi-Khiavi H; Mehranfar S; Rezaei R; Motallebnezhad M
J Cell Physiol; 2019 Jul; 234(7):9966-9981. PubMed ID: 30537008
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
15. Novel Techniques to Study the Bone-Tumor Microenvironment.
Shupp AB; Kolb AD; Bussard KM
Adv Exp Med Biol; 2020; 1225():1-18. PubMed ID: 32030644
[TBL] [Abstract][Full Text] [Related]
16. Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment.
Zarrer J; Haider MT; Smit DJ; Taipaleenmäki H
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092997
[TBL] [Abstract][Full Text] [Related]
17. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR
J Pathol; 2016 Jun; 239(2):218-30. PubMed ID: 27174786
[TBL] [Abstract][Full Text] [Related]
18. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
19. Immune Modulation of Metastatic Niche Formation in the Bone.
Cheng X; Wang Z
Front Immunol; 2021; 12():765994. PubMed ID: 34745140
[TBL] [Abstract][Full Text] [Related]
20. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
